BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 33210239)

  • 21. Impact of
    Sonni I; Eiber M; Fendler WP; Alano RM; Vangala SS; Kishan AU; Nickols N; Rettig MB; Reiter RE; Czernin J; Calais J
    J Nucl Med; 2020 Aug; 61(8):1153-1160. PubMed ID: 31924715
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Standardised uptake values as determined on prostate-specific membrane antigen positron emission tomography/computed tomography is associated with oncological outcomes in patients with prostate cancer.
    Bodar YJL; Veerman H; Meijer D; de Bie K; van Leeuwen PJ; Donswijk ML; van Moorselaar RJA; Hendrikse NH; Boellaard R; Oprea-Lager DE; Vis AN
    BJU Int; 2022 Jun; 129(6):768-776. PubMed ID: 35166426
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prospective Evaluation of
    Lopci E; Lughezzani G; Castello A; Saita A; Colombo P; Hurle R; Peschechera R; Benetti A; Zandegiacomo S; Pasini L; Casale P; Pietro D; Bevilacqua G; Balzarini L; Buffi NM; Guazzoni G; Lazzeri M
    Eur Urol Focus; 2021 Jul; 7(4):764-771. PubMed ID: 32312701
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pilot study of the diagnostic utility of
    Vlachostergios PJ; Niaz MJ; Thomas C; Christos PJ; Osborne JR; Margolis DJA; Khani F; Bander NH; Scherr DS; Tagawa ST
    Prostate; 2022 Mar; 82(4):483-492. PubMed ID: 34985786
    [TBL] [Abstract][Full Text] [Related]  

  • 25. What's behind
    Rüschoff JH; Ferraro DA; Muehlematter UJ; Laudicella R; Hermanns T; Rodewald AK; Moch H; Eberli D; Burger IA; Rupp NJ
    Eur J Nucl Med Mol Imaging; 2021 Nov; 48(12):4042-4053. PubMed ID: 34386839
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The Theranostic PSMA Ligand PSMA-617 in the Diagnosis of Prostate Cancer by PET/CT: Biodistribution in Humans, Radiation Dosimetry, and First Evaluation of Tumor Lesions.
    Afshar-Oromieh A; Hetzheim H; Kratochwil C; Benesova M; Eder M; Neels OC; Eisenhut M; Kübler W; Holland-Letz T; Giesel FL; Mier W; Kopka K; Haberkorn U
    J Nucl Med; 2015 Nov; 56(11):1697-705. PubMed ID: 26294298
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Establishment and prospective validation of an SUV
    Jiao J; Kang F; Zhang J; Quan Z; Wen W; Zhao X; Ma S; Wu P; Yang F; Guo W; Yang X; Yuan J; Shi Y; Wang J; Qin W
    Theranostics; 2021; 11(17):8396-8411. PubMed ID: 34373749
    [No Abstract]   [Full Text] [Related]  

  • 28.
    Calais J; Ceci F; Eiber M; Hope TA; Hofman MS; Rischpler C; Bach-Gansmo T; Nanni C; Savir-Baruch B; Elashoff D; Grogan T; Dahlbom M; Slavik R; Gartmann J; Nguyen K; Lok V; Jadvar H; Kishan AU; Rettig MB; Reiter RE; Fendler WP; Czernin J
    Lancet Oncol; 2019 Sep; 20(9):1286-1294. PubMed ID: 31375469
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A Prospective Comparison of
    Anttinen M; Ettala O; Malaspina S; Jambor I; Sandell M; Kajander S; Rinta-Kiikka I; Schildt J; Saukko E; Rautio P; Timonen KL; Matikainen T; Noponen T; Saunavaara J; Löyttyniemi E; Taimen P; Kemppainen J; Dean PB; Blanco Sequeiros R; Aronen HJ; Seppänen M; Boström PJ
    Eur Urol Oncol; 2021 Aug; 4(4):635-644. PubMed ID: 32675047
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The diagnostic value of PET/CT imaging with the (68)Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer.
    Afshar-Oromieh A; Avtzi E; Giesel FL; Holland-Letz T; Linhart HG; Eder M; Eisenhut M; Boxler S; Hadaschik BA; Kratochwil C; Weichert W; Kopka K; Debus J; Haberkorn U
    Eur J Nucl Med Mol Imaging; 2015 Feb; 42(2):197-209. PubMed ID: 25411132
    [TBL] [Abstract][Full Text] [Related]  

  • 31.
    Fitzpatrick C; Lynch O; Marignol L
    Anticancer Res; 2017 Jun; 37(6):2753-2760. PubMed ID: 28551611
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Incremental Impact of [
    Szigeti F; Schweighofer-Zwink G; Meissnitzer M; Hauser-Kronberger C; Hitzl W; Kunit T; Forstner R; Pirich C; Beheshti M
    Mol Imaging Biol; 2022 Feb; 24(1):50-59. PubMed ID: 34519966
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Multiphasic
    Beheshti M; Manafi-Farid R; Geinitz H; Vali R; Loidl W; Mottaghy FM; Langsteger W
    J Nucl Med; 2020 Oct; 61(10):1484-1490. PubMed ID: 32060214
    [TBL] [Abstract][Full Text] [Related]  

  • 34. MRI versus ⁶⁸Ga-PSMA PET/CT for gross tumour volume delineation in radiation treatment planning of primary prostate cancer.
    Zamboglou C; Wieser G; Hennies S; Rempel I; Kirste S; Soschynski M; Rischke HC; Fechter T; Jilg CA; Langer M; Meyer PT; Bock M; Grosu AL
    Eur J Nucl Med Mol Imaging; 2016 May; 43(5):889-897. PubMed ID: 26592938
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Primary lymph-node staging with
    Corona-Montes VE; González-Cuenca E; Fernández-Noyola G; Olarte-Casas MA; Bobadilla-Salazar D; Medrano-Urtecho HM; Asimakopoulos AD
    Urol Oncol; 2021 Aug; 39(8):494.e1-494.e6. PubMed ID: 33223371
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Is there a utility of adding skeletal imaging to 68-Ga-prostate-specific membrane antigen-PET/computed tomography in initial staging of patients with high-risk prostate cancer?
    Raju S; Sharma A; Patel C; Sahoo R; Das CJ; Kumar S; Sharma A; Kumar R
    Nucl Med Commun; 2020 Nov; 41(11):1183-1188. PubMed ID: 32796451
    [TBL] [Abstract][Full Text] [Related]  

  • 37.
    Liu C; Liu T; Zhang Z; Zhang N; Du P; Yang Y; Liu Y; Yu W; Li N; Gorin MA; Rowe SP; Zhu H; Yan K; Yang Z
    J Nucl Med; 2020 Sep; 61(9):1314-1319. PubMed ID: 32034111
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Detection and localisation of primary prostate cancer using
    Kalapara AA; Nzenza T; Pan HYC; Ballok Z; Ramdave S; O'Sullivan R; Ryan A; Cherk M; Hofman MS; Konety BR; Lawrentschuk N; Bolton D; Murphy DG; Grummet JP; Frydenberg M
    BJU Int; 2020 Jul; 126(1):83-90. PubMed ID: 31260602
    [TBL] [Abstract][Full Text] [Related]  

  • 39. PSMA-PET and micro-ultrasound potential in the diagnostic pathway of prostate cancer.
    Lopci E; Lughezzani G; Castello A; Colombo P; Casale P; Saita A; Buffi NM; Guazzoni G; Chiti A; Lazzeri M
    Clin Transl Oncol; 2021 Jan; 23(1):172-178. PubMed ID: 32447644
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Radiomic features from PSMA PET for non-invasive intraprostatic tumor discrimination and characterization in patients with intermediate- and high-risk prostate cancer - a comparison study with histology reference.
    Zamboglou C; Carles M; Fechter T; Kiefer S; Reichel K; Fassbender TF; Bronsert P; Koeber G; Schilling O; Ruf J; Werner M; Jilg CA; Baltas D; Mix M; Grosu AL
    Theranostics; 2019; 9(9):2595-2605. PubMed ID: 31131055
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.